SLEURO TODAY

Home / Science & Publications

Over a course of 46 years, clinical presentation of lupus nephritis (LN) has become less severe in the last years, leading to a better long-term renal survival: The indispensable role of renal biopsy and the need for a low-threshold to perform renal biopsy

Comment on: Changing patterns in clinical–histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis.Moroni G, Vercelloni PG, Quaglini S, et al Ann Rheum Dis. 2018 Sep;77(9):1318-1325. doi: 10.1136/annrheumdis-2017-212732. Epub 2018 May 5. Commented by: Dimitrios T. Boumpas, Medical School, National and Kapodistrian University of Athens, Greece … Read more

Trial in Anifrolumab in Active Systemic Lupus Erythematosus

Comment on: ”Trial in Anifrolumab in Active Systemic Lupus Erythematosus” by E.F Morand, R. Furie, Y. Tanaka I.N:Bruce, A.D Askanase, C Riches, S-C Bae, P.Z Brohawn, L Pindea, A Berglind and R Tummala for the TULIP-2 Investigators. Published in NEJM 2020; 382:211-21 Commented by: Elisabet Svenungsson, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden Background: We … Read more

Withdrawal of low-dose prednisone in sle patients with a clinically quiescent disease for more than 1 year: a randomised controlled trial.

Comment on: “Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised controlled trial” by Mathian A, Pha M, Haroche J, Cohen-Aubart F, Hie M, Pineton de Chambron M et al. Annals of the Rheumatic Diseases on-line first Dec 18 2019. Doi 10.1136/annrheumdis-2019-216303. Commented by: Anisur … Read more

Toward a novel prediction marker in SLE?

Comment on: Alexis Mathian, Suzanne Mouries-Martin, Karim Dorgham et al. Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis 2019;0:1–8. doi:10.1136/annrheumdis-2019-215571. Commented by: Carlo Chizzolini, University of Geneva | UNIGE, Division of Immunology and Allergology. The importance in SLE pathogenesis of type-I interferon (IFN-I) has been well documented … Read more

Being in the right place at the right time: when position matters

Comment on: Burke et al., “Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain.” Sci. Transl. Med. 11, eaaw1736 (2019) Commented by: Andrea Doria, Mariele Gatto, Unit of Rheumatology, University of Padova, Italy. Email: adoria@unipd.it The advent of small molecules in the treatment of rheumatic diseases is part of a … Read more

2019 EULAR/ACR SLE classification criteria in practice

Comment on: Aringer M., Costenbader K., Daikh D., et al. “2019 European League against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus” Ann Rheum Dis 2019;78:1151–9. Papers 1-11. Commented by: Matthias Schneider, Heinrich-Heine- Universität Düsseldorf, HHU, Policlinic and Hiller Research Unit Rheumatology. E-mail: Matthias.Schneider@med.uni-duesseldorf.de The new EULAR/ACR are published and will change the perspective … Read more

EULAR recommendations for the management of antiphospholipid syndrome in adults

Comment on: EULAR recommendations for the management of antiphospholipid syndrome in adults. Tektonidou MG, et al. Ann Rheum Dis. 2019;78:1296-1304. Commented by: Maria G. Tektonidou, MD, PhD, Associate Professor of Rheumatology. Head of Rheumatology Unit, First Department of Propaedeutic Internal Medicine, School of Medicine, University of Athens, Greece Due to the rarity of Antiphospholipid syndrome … Read more

Tubular cell and keratinocyte single-cell transcriptomics in lupus nephritis

Comment on: Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Dar E, et al. Nat Immunol. 2019;20:915-927. Commented by: Maria G. Tektonidou, MD, PhD, Associate Professor of Rheumatology. Head of Rheumatology Unit, First Department of Propaedeutic Internal Medicine, School of Medicine, University of Athens, Greece … Read more

Low disease activity versus remission in SLE: is it ok to be “mediocre”?

Comment on: Petri M, Madger LS. Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. Arthritis Rheum 2018; 1790– 1795 Commented by: Laurent Arnaud, Department of Rheumatology, National Reference Centre for Rare Systemic and Autoimmune Diseases East South-West (RESO), Strasbourg, France. Twitter: @Lupusreference. Email: Laurent.arnaud@chru-strasbourg.fr … Read more